Logo image of NCI

NEO-CONCEPT INTL GROUP HLD-A (NCI) Stock Fundamental Analysis

NASDAQ:NCI - Nasdaq - KYG6421C1125 - Common Stock - Currency: USD

0.36  -0.04 (-10%)

After market: 0.36 0 (0%)

Fundamental Rating

4

NCI gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 48 industry peers in the Textiles, Apparel & Luxury Goods industry. NCI has only an average score on both its financial health and profitability. NCI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

NCI had positive earnings in the past year.
In the past year NCI had a positive cash flow from operations.
NCI Yearly Net Income VS EBIT VS OCF VS FCFNCI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -20M -40M

1.2 Ratios

NCI has a Return On Assets of 6.99%. This is in the better half of the industry: NCI outperforms 66.67% of its industry peers.
The Return On Equity of NCI (16.68%) is better than 68.75% of its industry peers.
With a decent Return On Invested Capital value of 10.33%, NCI is doing good in the industry, outperforming 64.58% of the companies in the same industry.
Industry RankSector Rank
ROA 6.99%
ROE 16.68%
ROIC 10.33%
ROA(3y)13.48%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NCI Yearly ROA, ROE, ROICNCI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

With a Profit Margin value of 3.01%, NCI perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
NCI's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 3.83%, NCI is doing worse than 64.58% of the companies in the same industry.
In the last couple of years the Operating Margin of NCI has grown nicely.
With a Gross Margin value of 20.90%, NCI is not doing good in the industry: 87.50% of the companies in the same industry are doing better.
NCI's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 3.83%
PM (TTM) 3.01%
GM 20.9%
OM growth 3Y38.21%
OM growth 5YN/A
PM growth 3Y14.72%
PM growth 5YN/A
GM growth 3Y30.72%
GM growth 5YN/A
NCI Yearly Profit, Operating, Gross MarginsNCI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 5 10 15 20

More info and screens

6

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so NCI is destroying value.
The number of shares outstanding for NCI remains at a similar level compared to 1 year ago.
Compared to 1 year ago, NCI has an improved debt to assets ratio.
NCI Yearly Shares OutstandingNCI Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M
NCI Yearly Total Debt VS Total AssetsNCI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 2.87 indicates that NCI is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.87, NCI is in line with its industry, outperforming 52.08% of the companies in the same industry.
NCI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.87
ROIC/WACC0.88
WACC11.67%
NCI Yearly LT Debt VS Equity VS FCFNCI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M -20M 40M -40M -60M

2.3 Liquidity

NCI has a Current Ratio of 1.84. This is a normal value and indicates that NCI is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.84, NCI perfoms like the industry average, outperforming 47.92% of the companies in the same industry.
NCI has a Quick Ratio of 1.75. This is a normal value and indicates that NCI is financially healthy and should not expect problems in meeting its short term obligations.
NCI has a Quick ratio of 1.75. This is amongst the best in the industry. NCI outperforms 83.33% of its industry peers.
Industry RankSector Rank
Current Ratio 1.84
Quick Ratio 1.75
NCI Yearly Current Assets VS Current LiabilitesNCI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

NCI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1396.27%, which is quite impressive.
The Earnings Per Share has been growing by 15.32% on average over the past years. This is quite good.
NCI shows a strong growth in Revenue. In the last year, the Revenue has grown by 24.91%.
Measured over the past years, NCI shows a decrease in Revenue. The Revenue has been decreasing by -0.68% on average per year.
EPS 1Y (TTM)1396.27%
EPS 3Y15.32%
EPS 5YN/A
EPS Q2Q%89.28%
Revenue 1Y (TTM)24.91%
Revenue growth 3Y-0.68%
Revenue growth 5YN/A
Sales Q2Q%35.28%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NCI Yearly Revenue VS EstimatesNCI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 6.00, the valuation of NCI can be described as very cheap.
Based on the Price/Earnings ratio, NCI is valued cheaply inside the industry as 91.67% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.60. NCI is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 6
Fwd PE N/A
NCI Price Earnings VS Forward Price EarningsNCI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

85.42% of the companies in the same industry are more expensive than NCI, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 5.75
NCI Per share dataNCI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

NCI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEO-CONCEPT INTL GROUP HLD-A

NASDAQ:NCI (6/12/2025, 8:14:39 PM)

After market: 0.36 0 (0%)

0.36

-0.04 (-10%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Durables & Apparel
GICS IndustryTextiles, Apparel & Luxury Goods
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.99%
Inst Owner Change0%
Ins Owners1.9%
Ins Owner Change0%
Market Cap7.32M
Analysts60
Price TargetN/A
Short Float %3.32%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 6
Fwd PE N/A
P/S 0.18
P/FCF N/A
P/OCF 134.09
P/B 1.01
P/tB 1.33
EV/EBITDA 5.75
EPS(TTM)0.06
EY16.67%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)0
OCFY0.75%
SpS1.97
BVpS0.36
TBVpS0.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 6.99%
ROE 16.68%
ROCE 12.52%
ROIC 10.33%
ROICexc 11.41%
ROICexgc 13.51%
OM 3.83%
PM (TTM) 3.01%
GM 20.9%
FCFM N/A
ROA(3y)13.48%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)8.04%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y38.21%
OM growth 5YN/A
PM growth 3Y14.72%
PM growth 5YN/A
GM growth 3Y30.72%
GM growth 5YN/A
F-Score6
Asset Turnover2.32
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 884.5%
Cap/Sales 6.09%
Interest Coverage 3.64
Cash Conversion 3.01%
Profit Quality N/A
Current Ratio 1.84
Quick Ratio 1.75
Altman-Z 2.87
F-Score6
WACC11.67%
ROIC/WACC0.88
Cap/Depr(3y)604.44%
Cap/Depr(5y)N/A
Cap/Sales(3y)2.96%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1396.27%
EPS 3Y15.32%
EPS 5YN/A
EPS Q2Q%89.28%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)24.91%
Revenue growth 3Y-0.68%
Revenue growth 5YN/A
Sales Q2Q%35.28%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y63.89%
EBIT growth 3Y37.27%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y62.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y100.87%
OCF growth 3Y-65.32%
OCF growth 5YN/A